Studies have shown that the PI3K/AKT-mTOR pathway plays a role in the development of BRAFi resistance by triggering a surrogate survival signaling, leading to resistant BRAFi-treated melanoma cells [57,58]. Here, PIK3CA is linked to melanoma.